Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novacyt ( (FR:ALNOV) ) just unveiled an announcement.
Novacyt reported unaudited 2025 revenues of about £20.0m, marginally up from £19.6m in 2024 and broadly in line with market expectations, while maintaining a strong cash position of £19.2m and remaining debt-free. Underlying revenue grew around 4% (5% at constant currency) despite the divestment of its Taiwan service lab, with clinical sales up 3% to £13.8m, including double‑digit growth in NIPT technologies, and instrumentation sales climbing more than 25% to £2.5m, offset by a roughly 10% decline in the research-use-only segment. APAC was the fastest-growing region with about 10% growth, driven by reproductive health products, and the Group delivered three consecutive periods of half-year revenue growth, while EBITDA losses are expected to at least meet, or improve on, forecasts thanks to tight cost control. Commercially, the company gained traction with its new LightBench Discover long-read sequencing instrument, placing 10 units since its July 2025 launch and building a strong pipeline, introduced the Primerdesign exsig Mag RapidBead Pro Extraction Kit to bolster its RUO offering, and advanced beta testing of Yourgene’s Insight DPYD assay with international precision-medicine experts ahead of a planned launch in the first half of 2026, underscoring management’s efforts to stabilise the business and refocus it on innovation-led growth.
More about Novacyt
Novacyt is an international molecular diagnostics company focused on genomic medicine, developing, manufacturing and commercialising molecular assays and instrumentation that provide end-to-end workflows from sample to result. Its activities span three segments: clinical in vitro diagnostics in reproductive health, precision medicine and infectious diseases; next-generation DNA size-selection and rapid PCR instrumentation; and research-use-only services including high-performance qPCR assays and genomic sequencing for human, animal and environmental applications. Headquartered in France with operations in the UK, Singapore, the US and Canada, Novacyt sells into more than 65 countries and is listed on AIM in London and Euronext Growth in Paris.
For an in-depth examination of ALNOV stock, go to TipRanks’ Overview page.